September 2, 2024 5:17 PM
Sanofi’s mixed fortunes in MS drug trials has market focus on win
Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive surprise succeeded in a study on a less common form of progressive MS. Investors fo...
